通过增强肠道粘膜屏障功能和抗氧化能力,Eucommia ulmoides多糖改性纳米有效缓解了DSS诱导的结肠炎
Ruihua Ye1, Qingyun Guo2, Jiaqiang Huang3,4
1College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China.
Journal of nanobiotechnology
|July 12, 2023
概括
新的纳米颗粒 (EUP-SeNP) 显示出治疗性结肠炎 (UC),一种常见的炎症性肠病 (IBD) 的前景. 这项研究表明,EUP-SeNP通过调节肠道微生物群和抑制关键炎症途径,有效地减少小鼠的结肠炎症状和炎症.
科学领域:
- 胃肠病学 胃肠病学
- 纳米医学是一种纳米医学.
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种普遍存在的炎症性肠病 (IBD),目前没有治愈方法,需要新的治疗策略.
- 纳米颗粒 (SeNP) 具有显著的生物活性,使其成为治疗开发的潜在候选者.
研究的目的:
- 研究Eucommia ulmoides多糖 (EUP) 修饰的纳米颗粒 (EUP-SeNP) 的治疗潜力,用于治疗硫酸 (DSS) 诱导的结肠炎.
- 阐明EUP-SeNP在小鼠模型和肠上皮细胞系中改善大肠炎的潜在机制.
主要方法:
- 合成和描述EUP-SeNP (大约170纳米).
- 在小鼠中诱导大肠炎使用3%的硫酸 (DSS).
- 对口服EUP-SeNP治疗大肠炎的治疗效果的评估,包括组织学分析,屏障功能,细胞因子水平和微生物组合.
- 使用肠道上皮细胞系进行体外机制研究,以评估对TRL-4/NF-κB信号通路的影响.
主要成果:
- 在小鼠中,EUP-SeNP治疗显著缓解了DSS诱导的大肠炎,重量恢复,疾病活性指数 (DAI) 降低和结肠组织学改善证明了这一点.
- 治疗增强了结肠的抗氧化能力,并调节了大肠炎小鼠的肠道微生物组合.
- 机理学研究证实,EUP-SeNP抑制了肠道上皮细胞中TRL-4/NF-κB信号通路的LPS诱导激活.
结论:
- 在性结肠炎的小鼠模型中,EUP-SeNP显示出显著的治疗疗效.
- 这些发现表明,EUP-SeNP通过增强抗氧化能力,调节肠道微生物群,并抑制TRL-4/NF-κB炎症途径来起作用.
- 这项研究为治疗炎症性肠病提供了潜在的治疗参考.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217


